Loading clinical trials...
Loading clinical trials...
A Dose Ascending, Open Phase I Clinical Study to Evaluate the Safety, Tolerability , Pharmacokinetics Characteristics and Preliminary Effectiveness of VG161 in Subjects with Advanced Primary Liver Cancer
Conditions
Interventions
Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))
Locations
1
China
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Start Date
March 16, 2021
Primary Completion Date
March 21, 2022
Completion Date
December 31, 2024
Last Updated
September 19, 2024
NCT07466602
NCT06914648
NCT06766643
NCT06430983
NCT05714124
NCT06325267
Lead Sponsor
CNBG-Virogin Biotech (Shanghai) Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions